Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q4 FY2023 Earnings Presentation
27 slides from Rossari Biotech's earnings presentation, Apr 30, 2023
Slide 1: Rossari – Q4 FY23 Earnings Presentation cover letter
ROSSARI making you more competitive April 30, 2023 DCS-CRD Listing Compliance BSELimited National Stock Exchange of India Ltd. First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No.C/1, 'G'Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400
Slide 2: Rossari Biotech Limited Q4 & FY23 Results Presentation
Rossari Biotech Limited Q4 & FY23 Results Presentation April 29, 2023
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to b
Slide 4: Q4 & FY23 Results Overview
Q4 & FY23 Results Overview 3
Slide 5: Q4 FY23 – Key Financial Highlights
Q4 FY23 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. crore) (Rs. crore) (Rs. crore) 54.6 54.2 52.3 29.0 406.5 438.9 25.7 389.3 24.1 Q4 FY23 Q3 FY23 Q4 FY22 Q4 FY23 Q3 FY23 Q4 FY22 Q4 FY23 Q3 FY23 Q4 FY22 Shift % (Y-o-Y) (7.4%) 4.4% 20.3% Shift % (Q-o-Q) 4.4% 0.7% 12.8% Margins
Slide 6: FY23 – Key Financial Highlights
FY23 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. crore) (Rs. crore) (Rs. crore) 107.3 97.7 1655.9 223.0 1483.0 183.4 FY23 FY22 FY23 FY22 FY23 FY22 Shift % (Y-o-Y) 11.7% 21.6% 9.8% Margins (%) 13.5% 12.4% 6.5% 6.6% Note: 1) All figures, unless mentioned otherwise, are on a cons
Slide 7: Management Message
Management Message Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We are pleased to close the year on a steady note, with revenues increasing by 4.4% on a Q-o-Q basis. While we faced sev
Slide 8: Key Developments
Key Developments Successfully acquired the final tranche of Tristar Intermediates • Completed acquisition of additional 16% stake in Tristar Intermediates (Tristar) on 12th April 2023. Accordingly, Rossari now holds 100% in the company o Acquired the remaining stake through internal accruals • In Ju
Slide 9: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated Y-o-Y Change Y-o-Y Change Particulars (Rs. crore) Q4 FY23 Q4 FY22 FY23 FY22 (%) (%) Revenues from Operations 406.5 438.9 (7%) 1655.9 1,482.9 12% Total Expenditure • COGS 286.3 324.4 (12%) 1171.4 1,107.8 6% • Employee benefits expense 26.8 22.2 21% 98.6 67.9 45%
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY AND LIABILITIES CONSOLIDATED CONSOLIDATED ASSETS CONSOLIDATED CONSOLIDATED As on 31st March 2023 As on 31st March 2022 As on 31st March 2023 As on 31st March 2022 Particulars (Rs. crore) Particulars (Rs. crore) (Audited) (Audited) (Audited) (Audited) EQUITY ASSETS E
Slide 11: Consolidated Cash Flows
Consolidated Cash Flows CASH FLOW CONSOLIDATED CONSOLIDATED CASH FLOW CONSOLIDATED CONSOLIDATED As on 31st March 2023 As on 31st March 2022 As on 31st March 2023 As on 31st March 2022 Particulars (Rs. crore) Particulars (Rs. crore) (Audited) (Audited) (Audited) (Audited) Cash flows from operating ac
Slide 12: Q4 FY23 - Segment-wise Details
Q4 FY23 - Segment-wise Details Segment-wise Revenue Break-up (Rs. crore) Q4 FY23 Q3 FY232 Q4 FY22 303.7 265.4 271.2 98.5 109.8 89.5 42.5 28.7 25.4 HPPC TSC AHN Shift (Y-o-Y) % (12.6%) (10.3%) 67.3% Shift (Q-o-Q) % (2.1%) 10.1% 48.1% Note: 1) All figures, unless mentioned otherwise, are on a consolid
Slide 13: FY23 - Segment-wise Details
FY23 - Segment-wise Details Segment-wise Revenue Break-up (Rs. crore) FY22 FY23 1156.9 966.1 404.8 373.2 112.2 125.7 HPPC TSC AHN Shift (Y-o-Y) % 19.7% (8.5%) 13.5% Note: 1) All figures, unless mentioned otherwise, are on a consolidated basis 2) Home, Personal Care and Performance Chemicals (HPPC);
Slide 14: Q4 FY23 - Financial and Operational Discussions
Q4 FY23 - Financial and Operational Discussions Net Revenues Q4 FY23 Revenues from operations stood at Rs. 406.5 crore Standalone revenues reported improved traction, leading to a 11.3% Q-o-Q growth o HPPC and Textiles segments reported stable performance during the quarter despite a challenging o
Slide 15: Company Overview
Company Overview 14
Slide 16: Rossari – At a Glance
Rossari – At a Glance Technocrat promoters with 45+ 8* 354,100* 4* 34% 24% cumulative years of Manufacturing MTPA Revenue CAGR % PAT CAGR % experience in the R&D Facilities facilities Capacity Installed (FY19-23) (FY19-23) specialty chemicals industry Rossari – A Specialty-Chemical manufacturer prov
Slide 17: Business Overview
Business Overview One of the leading specialty chemicals manufacturer delivering differentiated & tailor-made solutions across Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health and Nutrition (AHN) businesses HPPC TSC AHN One of the fastest-gr
Slide 18: Strengthening Market Presence
Strengthening Market Presence Growing client base Diversifying of over 1,000 customer base to customers both lower India and concentration risk International Widening Increasingly tapping distribution new segments across network to drive domestic and reach international markets Company’s focus towar
Slide 19: Robust Manufacturing Capabilities
Robust Manufacturing Capabilities Located on 8.6 acres of land Manufacturing Fungible manufacturing capabilities for powders, granules and liquids Facility at Facility has a comprehensive range of testing & packaging capabilities Silvassa Effluent treatment facility, with 2,500 MT bulk stora
Slide 20: Strategic Growth Levers
Strategic Growth Levers Augmenting product portfolio with enhanced emphasis on green solutions Increase wallet share across existing customer base while also tapping new customer segments Identifying and developing new niches in product offerings by leveraging R&D capabilities Capitalize on cros
Slide 21: Recent Inorganic Initiatives
Recent Inorganic Initiatives Executed two synergistic acquisitions and one strategic investment in FY 2022 complementing the ethos of Rossari’s business model SF Unitop Chemicals Tristar Intermediates Romakk Chemicals Prominent player in the field of Preservatives, Primarily engaged in the business
Slide 22: Key Synergies from Recent Acquisitions
Key Synergies from Recent Acquisitions Strategic & value-accretive acquisitions accelerate growth and drive economies of scale Augmented Pooling together Expansion of of related Inorganic presence in Extension of addressable technologies investments Specialty manufacturing domestic and within operat
Slide 23: Focus on Green & Sustainable Chemical Solutions
Focus on Green & Sustainable Chemical Solutions Specialists in producing environmentally- benign substitutes that replace legacy and harmful products Focus on green, sustainable and cost neutral products Minimizing carbon footprint of manufacturing processes while maximizing customer benefits Aggres
Slide 24: Annexure
ROSSARI making you more competitive Annexure 23
Slide 25: Conference Call Details
Conference Call Details Q4 FY23 Earnings Conference Call Time • 5:00 p.m. IST on Tuesday, May 2, 2023 To enable participants to connect to the conference call without Pre-registration having to wait for an operator, please register at the below mentioned link: Primary dial-in number • + 91 22 6280 1
Slide 26: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a For further information, please contact: Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Manasi Nisal Headquartered at Mumbai, India, the Company operates Ro
Slide 27: Thank you
Thank y#u making you more competitive